The firm's Guardant360 assay will be used first to test patients for ERBB2 mutations, then guide patients to a variety of treatment arms.
The Financial Times reports that CRISPR-based biotechs are about to start human studies of gene-editing treatments.
Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.
A new study in JAMA finds that genetic tests might not be able to determine what diet is right for someone seeking to lose weight.
Nohla will use Karius' NGS plasma test for pathogen detection in a randomized trial evaluating Nohla's lead product, a cellular therapy called NLA101.
BMS amended an ongoing Phase III study of Opdivo and Yervoy to evaluate outcomes based on tumor mutational burden using Foundation Medicine's NGS companion diagnostic.
The analysis of HER2 and HER3 mutation carriers emphasizes how these studies can lead both to broadening and to narrowing of the patient populations for targeted drugs.
Foundation Medicine will provide genomic profiling for the EORTC's Screening Patients for Efficient Clinical Trial Access program.
With fewer rules, doctors in China are moving ahead with CRISPR clinical trials, the Wall Street Journal reports.
Stat News reports that researchers are not good at predicting whether a clinical trial will be successful.
Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.
The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.
Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.
In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.